Lu-177 PSMA therapy, also known as Lutetium-177 PSMA therapy, is an advanced targeted radionuclide treatment used for selected patients with advanced or metastatic prostate cancer. It is generally considered when prostate cancer has progressed despite other standard treatments and when testing confirms that the cancer cells express PSMA (Prostate-Specific Membrane Antigen).
How Lu-177 PSMA Therapy Works
Before treatment, doctors may perform appropriate imaging, such as a PSMA PET scan, to determine whether the cancer is suitable for PSMA-targeted therapy. During treatment, Lutetium-177 attached to a PSMA-targeting molecule travels to PSMA-positive cancer cells and delivers radiation directly to those cells. This targeted approach is designed to limit radiation exposure to surrounding healthy tissue while treating cancer sites throughout the body.
Who May Benefit?
Lu-177 PSMA therapy may be considered for carefully selected patients with metastatic castration-resistant prostate cancer (mCRPC) or other advanced PSMA-positive prostate cancers. Eligibility depends on factors such as previous treatments, PSMA imaging findings, kidney function, blood counts, overall health, and the treating specialist's assessment.
Benefits and Safety
Potential benefits may include helping control disease, reducing cancer-related symptoms, and slowing disease progression in appropriate patients. Possible side effects include dry mouth, fatigue, nausea, reduced blood cell counts, and kidney-related effects. Your oncology and nuclear medicine team will explain the expected benefits, risks, precautions, and follow-up requirements before treatment.
Treatment and Follow-Up
Lu-177 PSMA therapy is administered under specialist supervision. Patients may require multiple treatment cycles depending on their clinical response and treatment plan. Regular blood tests, imaging, and medical reviews help monitor response and safety throughout the treatment course.